Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome

Thrombosis Research

Volumn 121, Issue 2, 2007, Pages 175-181

  Skeppholm, Mika ^a   Wallén, N Håkan ^a   Malmqvist, Karin ^a   Kallner, Anders ^b   Antovic, Jovan P ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute coronary syndrome (ACS); Chromogenic substrates; ELISA; Kinetic assay; Polymorphism; TAFI

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORRELATION COEFFICIENT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOCHEMISTRY; MALE; PRIORITY JOURNAL; STUDENT T TEST;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MIDDLE AGED;

EID: 35349014786     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.03.021     Document Type: Article

References (19)

1. Antovic J.P. Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis (review). Clin Lab 49 (2003) 475-486
2. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
3. Juhan-Vague I., Renucci J.F., Grimaux M., Morange P.E., Gouvernet J., Gourmelin Y., et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 20 (2000) 2156-2161
4. Van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
5. Eichinger S., Schönauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
6. Leebeek F.W.G., van Goor M.P.J., Guimares A.H.C., Brouwers G.-J., deMaat M.P.M., Dippel D.W.J., et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3 (2005) 2211-2218
7. Montaner J., Ribo M., Monasterio J., Molina C.A., and Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34 (2003) 1038-1040
8. Silveira A., Schatterman K., Goossens F., Moor E., Scharpé S., Strömqvist M., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
9. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., et al. Plasma thrombin activatable-fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
10. Juhan-Vague I., Morange P.E., and on behalf of the PRIME Study Group. Very high TAFI antigen levels are associated with a lower hard core coronary events: the PRIME Study. J Thromb Haemost 1 (2003) 2243-2244
11. Brouwers G.-J., Leebeek F.W.G., Tanck M.W.T., Jukema J.W., Kluft C., and de Maat M.P.M. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90 (2003) 92-100
12. Hamsten A., Wiman B., de Faire U., and Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1557-1563
13. Guimares A.H.C., van Tilburg N.H., Vos H.L., Bertina R.M., and Rijken D.C. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 124 (2004) 659-665
14. Verdú J., Pascual M., Benlloch S., Snachez J., and Lucas J. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 95 (2006) 585-586
15. Kaftan O., Balcik O.S., Cipil H., Ozet G., Bavbek N., Koşar A., et al. Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis. Clin Appl Thromb Hemost 11 (2005) 449-454
16. Schatteman K.A., Gossens F.J., Scharpé S., Neels H.M., and Hendriks D.F. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade in human plasma. Clin Chem 45 (1999) 807-813
17. Chetaille P., Alessi M.C., Kouassi D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 (2000) 902-905
18. Skeppholm M, Wallén H, Blombäck M, Kallner A. Influence of anticoagulants on the measurements of plasma fibrinogen and CRP concentrations; - should citrate or EDTA be used? Scand J Clin Lab Invest [under revision, April 2007].
19. Cellai A.P., Antonucci E., Liotta A.A., Fedi S., Marcucci R., Falciani M., et al. TAFI activity and antigen plasma levels are not increased in acute coronary disease patients admitted to coronary care unit. Thromb Res 118 (2006) 495-500